MetLife director acquires 39 shares via dividends

MetLife director Laura J. Hay received 39 additional common shares through dividend reinvestment on deferred director compensation, increasing her reported holdings.

Available on EDGAR 09/10/2026 - 04:03 PM EDT Accepted by SEC EDGAR 09/10/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

METLIFE INC (MET) reported that director Laura J. Hay acquired 39 shares of common stock on September 8, 2026 at an imputed price of $95.50 per share. The acquisition reflects imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors, bringing her direct holdings to 6,357 shares.

Insider Trade Summary

Grant/Award: 39 shares

Grant/Award 1 txn

Insider Hay Laura J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	39	$95.50	$4K

Holdings After Transaction: Common Stock — 6,357 shares (Direct)

Holdings Before and After: Common Stock, 6,318 to 6,357 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Key Figures

Shares acquired: 39 shares Imputed price per share: $95.50 per share Total shares held after transaction: 6,357 shares +1 more

4 metrics

Shares acquired 39 shares Grant/award acquisition on September 8, 2026

Imputed price per share $95.50 per share Attributed to the 39-share acquisition on September 8, 2026

Total shares held after transaction 6,357 shares Director Laura J. Hay’s direct MetLife common stock holdings following the reported transaction

Transactions acquiring shares 1 transaction One grant or award acquisition reported in this Form 4

Key Terms

Imputed reinvestment of dividends, Deferred Compensation Plan for Non-Management Directors, deferred shares

3 terms

Imputed reinvestment of dividends financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan"

Deferred Compensation Plan for Non-Management Directors financial

"pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors"

deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock that have become payable"

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MET (MetLife) report for Laura J. Hay?

MetLife reported that director Laura J. Hay acquired 39 shares of MetLife common stock on September 8, 2026, recorded as a grant or award tied to dividend reinvestment on deferred shares.

At what price were the new MetLife (MET) shares attributed to Laura J. Hay?

The 39 acquired shares for Laura J. Hay were attributed an imputed price of $95.50 per share, as reported in the Form 4 for the September 8, 2026 transaction.

How many MetLife (MET) shares does Laura J. Hay hold after this transaction?

Following the September 8, 2026 acquisition, Laura J. Hay is reported as directly holding 6,357 shares of MetLife common stock.

What is the source of the additional MetLife (MET) shares reported for Laura J. Hay?

The additional 39 shares arose from imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors, according to the Form 4 footnote.

Was Laura J. Hay’s MetLife (MET) transaction under a Rule 10b5-1 trading plan?

The filing indicates that the Rule 10b5-1 checkbox is not affirmed for this Form 4, meaning the reported September 8, 2026 transaction is not identified as executed under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hay Laura J

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		A(1)		39	A	$95.5	6,357	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)